National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

2012

Adams R, Walsh C, Barry M, Fitzgerald O, Helliwell P.  Mapping models in Psoriatic Arthritis: Analysis from the GRACE dataset. ISPOR Berlin Nov 5-7 2012.

McCullagh L, Walsh C, Barry M. Integration of Value of Information Into the Decision Making Process in Ireland.  ISPOR 15th Annual European Congress, ICC Berlin in Berlin, Germany 3- 7 November 2012.

Fogarty E, Walsh C, Grehan S, Schmitz S, McGuigan C, Barry M, Tubridy N.  Modelling the Relationship between Disease Severity and Utility in Multiple Sclerosis.  ISPOR 15th Annual European Congress, November 2012, Berlin, Germany.

Fogarty E, Schmitz S, Walsh C, Barry M.  Combining RCT and Observational Data in a Mixed Treatment Comparison of Disease-Modifying-Therapies for Multiple Sclerosis.  ISPOR 15th Annual European Congress, November 2012, Berlin, Germany.

McGreal-Bellone A, Cleary S, Farrell G, Bergin C, Barry M, Kieran J.  Health-Related Quality of Life in HIV/HCV Co-Infected Patients in Ireland.  ISPOR 15th Annual European Congress.  November 2012, Berlin, Germany.

Kieran J, Mushtaq H, Bergin C, Norris S, Barry M.  Demographics and Health-State Utilities of Irish Patients with Hepatitis C Infection; Use of the 5-Level Eq-5d Questionnaire.  ISPOR 15th Annual European Congress, November 2012, Berlin, Germany.

Fogarty E, Walsh C, Schmitz S, McGuigan C, Barry M, Tubridy N.  The Impact of Increasing Disability on Quality of Life in Multiple Sclerosis.  ECTRIMS 28th congress, October 2012, Lyon, France.

Fogarty E, Walsh C, McGuigan C, Barry M, Tubridy N. The Impact of Increasing Disability on Quality of Life in Multiple Sclerosis.  Irish Neurological Association Meeting. May 2012, Cork, Ireland.

2011

McCullagh L, Usher C, Barry M. A review of the primary care prescribing of dabigatran etexilate and rivaroxaban in Ireland. ISPOR. 14th Annual European Congress, 5-8 November 2011, Madrid, Spain.

Fogarty E., Tilson L., Barry M. Cost of symptomatic drug therapy in multiple sclerosis Value in Health 2011 14:7 (A321) ISPOR  14th Annual European Congress, 5-8 November 2011, Madrid, Spain.

S Schmitz, R Adams, C Walsh, M Barry, O FitzGerald. A Bayesian Mixed Treatment Comparison Demonstrates Differences Between Anti-Tumour Necrosis Factor Agents in Rheumatoid Arthritis. ACR Nov 4-9 2011, Chicago

Usher C, Tilson L, Bennett K, Barry M. Evaluation of cost containment interventions introduced on the community drug schemes in Ireland using a national prescription claims database. ISPOR. 14th Annual European Congress, 5-8 November 2011, Madrid, Spain.

Usher C, Tilson L, Bennett K, Barry M. Evaluation of expenditure trends in Ireland. PPRI. 2nd Annual Conference, 29-30 September 2011, Vienna, Austria.

Usher C, Bennett K, Barry M. Introduction of a prescription charge on the community drug scheme in Ireland – what impact has it had on drug utilization?  ISPOR. 14th Annual European Congress, 5-8 November 2011, Madrid, Spain.

2010

Usher C, Tilson L, Barry M. Potential future impact of price control mechanisms on the community drug schemes in Ireland. HTAi. 7th Annual Meeting, 6–9th June 2010, Dublin, Ireland.

McCullagh L, Walsh C, Barry M.  An application of Value of Information analysis to decrease uncertainty. HTAi. 7th Annual Meeting, 6–9th June 2010, Dublin, Ireland.

McCullagh L, Walsh C, Barry M. Prioritising further research using the expected value of perfect information: Application to venous thromboembolism prophylaxis after total hip replacement. ISPOR. 13th Annual European Congress 7-10 November 2010. Prague, Czech Republic.

Cahir C. Fahey T. Teljeur C. Tilson L. Bennett K.  Cost-effective proton pump inhibitor prescribing: Potential strategies for more rational Prescribing. Pharmacoepidemiology and Drug Safety (2010) 19 SUPPL. 1 (S217-S218).

Wettermark B. Elseviers M. Godman B. Ronning M. Tilson L. Palcevski V.V. Methodological challenges in cross-national comparisons of drug utilization. Pharmacoepidemiology and Drug Safety (2010) 19 SUPPL. 1 (S16).

R. Adams, B. Craig , C. Walsh , B. Bresnihan, M. Barry , D. Veale , O. FitzGerald.  Revising THE Scoring System FOR THE Eq-5d Produces a Change IN Qaly, Which is Closer to Disease Measures in Inflammatory Arthritis. EULAR 2010

2009

Adams R., Teck Ng C., Lynch B., Saber T., Pontiflex E., Barry M., Molloy M., Grier A., Veale D., Bresnihan B., FitzGerald O. QOL Scores reflect disease activity both pre and post initiation of biologic therapy in patients with rheumatoid and psoriatic arthritis Rheumatology 2009 48 SUPPL. 1 (i158)

Adams R., Walsh C., Tilson L., FitzGerald O., Bresnihan B., Veale D., Barry M.  A calibration of the relationship between the HAQ, The SF-6D and the EQ-5D in inflammatory arthritis
Value in Health 2009 12:7 (A446-A447)

McCullagh L, Tilson L, Walsh C, Barry M. Cost-effectiveness of rivaroxaban and dabigatran etexilate for the prophylaxis of venous thromboembolism and associated long term complications after total hip replacement in Ireland. ISPOR. 12th Annual European Congress, 24-27 October 2009, Paris, France.

Sharp L. Tilson L. Whyte S. O’Ceilleachair A. Walsh C. Usher C. Tappenden. P. Chilcott J. Staines A. Comber H. Barry M. Cost-effectiveness of a population-based colorectal cancer screening  programme in Ireland. Value in Health (2009) 12:7 (A280).

Tilson L. O’Leary A. Usher C. Barry M. A review of pharmoeconomic evaluations of new and existing technologies by the national centre for pharmoeconomics in Ireland. Value in Health (2009) 12:7 (A250).

Heghes D.A. Tilson L. Drummond M.F.  Estimating drug costs in economic evaluations in Ireland and the UK: An analysis of practice and research recommendations.  Value in Health (2009) 12:3 (A6-A7).

R. C. Adams, A. Mumtaz, D. Veale, B. Bresnihan, M. Barry, O. FitzGerald.  Improvement in quality of life is demonstrated by improvement in bath disease activity scores. Eular2009